Insmed Yönetim

Yönetim kriter kontrolleri 2/4

Insmed CEO'su Will Lewis, Sep2012 tarihinde atandı, in görev süresi 11.5 yıldır. in toplam yıllık tazminatı $ 7.79M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.4% maaş ve 90.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.29% ine doğrudan sahiptir ve bu hisseler MX$ 184.59M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 9.8 yıldır.

Anahtar bilgiler

Will Lewis

İcra Kurulu Başkanı

US$7.8m

Toplam tazminat

CEO maaş yüzdesi	9.4%
CEO görev süresi	11.5yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	9.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Will Lewis'un ücretlendirmesi Insmed'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	n/a	n/a	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Tazminat ve Piyasa: Will 'nin toplam tazminatı ($USD 7.79M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.31M ).

Tazminat ve Kazançlar: Will şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Will Lewis (54 yo)

11.5yrs

Görev süresi

US$7,789,898

Tazminat

Mr. William H. Lewis, also known as Will, J.D., M.B.A., serves as Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January, 2024. He has been Chief Executive Officer and President at...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Lewis	President	11.5yrs	US$7.79m	0.29% MX$ 184.6m
Sara Bonstein	Chief Financial Officer	4.2yrs	US$3.43m	0.0035% MX$ 2.2m
Roger Adsett	Chief Operating Officer	4.3yrs	US$4.64m	0.040% MX$ 25.4m
John Wise	Chief Commercial Officer	4.3yrs	US$4.02m	0.030% MX$ 18.9m
Martina Flammer	Chief Medical Officer	4.3yrs	US$3.76m	0.0041% MX$ 2.6m
Brian Kaspar	Chief Scientific Officer	no data	Veri yok	Veri yok
Eleanor Barisser	Associate Director of Investor Relations	no data	Veri yok	Veri yok
Michael Smith	Chief Legal Officer & Corporate Secretary	2.7yrs	Veri yok	0.058% MX$ 37.1m
Mandy Fahey	Executive Director of Corporate Communications	no data	Veri yok	Veri yok
S. Schaeffer	Chief People Strategy Officer	11.2yrs	US$2.66m	0.025% MX$ 15.8m
Eugene Sullivan	Chief Product Strategy Officer	6.8yrs	US$1.69m	Veri yok
Neil Hughes	GM & Head of Europe	4.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: INSM * 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Lewis	President	11.5yrs	US$7.79m	0.29% MX$ 184.6m
David W. McGirr	Independent Director	10.4yrs	US$320.00k	0.049% MX$ 31.2m
Melvin Sharoky	Independent Director	22.8yrs	US$312.50k	0.22% MX$ 138.2m
Alfred Altomari	Independent Director	11.6yrs	US$312.70k	0.029% MX$ 18.5m
David Brennan	Lead Independent Director	9.8yrs	US$342.30k	0.064% MX$ 41.1m
Clarissa Desjardins	Independent Director	4.3yrs	US$315.00k	0.024% MX$ 15.3m
Elizabeth Anderson	Independent Director	5.3yrs	US$310.00k	0.029% MX$ 18.2m
Leo Lee	Independent Director	5.8yrs	US$315.00k	0.066% MX$ 42.2m
Carol Schafer	Independent Director	3.9yrs	US$315.00k	0.021% MX$ 13.7m

9.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INSM * 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.8 yıldır).

Insmed Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insufficient new directors

Insufficient new directors

President recently sold Mex$2.7m worth of stock

Insufficient new directors

Independent Director recently bought Mex$16m worth of stock

Recent updates

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024

Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Insufficient new directors

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Insufficient new directors

President recently sold Mex$2.7m worth of stock

Insufficient new directors

Independent Director recently bought Mex$16m worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021)

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Senior VP recently sold Mex$143k worth of stock

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021)

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Senior VP & General Counsel recently sold Mex$457k worth of stock

Senior VP & General Counsel recently sold Mex$457k worth of stock

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş